scholarly journals Perinatal outcome and long term neurological morbidity of offspring born to women with uterine rupture

2022 ◽  
Vol 226 (1) ◽  
pp. S220
Author(s):  
Moran Shahar ◽  
Gali Pariente ◽  
Eyal Sheiner ◽  
Tamar Wainstock
2017 ◽  
Vol 96 (2) ◽  
pp. 233-242 ◽  
Author(s):  
Cathrine Vedel ◽  
Anna Oldenburg ◽  
Katharina Worda ◽  
Helle Larsen ◽  
Anni Holmskov ◽  
...  

2020 ◽  
Vol 222 (1) ◽  
pp. S252-S253
Author(s):  
Narkis Hermon ◽  
Omri Zamstein ◽  
Tamar Wainstock ◽  
Eyal Sheiner

2019 ◽  
Vol 23 (3) ◽  
pp. 484-490 ◽  
Author(s):  
Amir Freud ◽  
Tamar Wainstock ◽  
Eyal Sheiner ◽  
Ron Beloosesky ◽  
Laura Fischer ◽  
...  

Author(s):  
Hagar Levy Shachar ◽  
Tamar Wainstock ◽  
Eyal Sheiner ◽  
Gali Pariente

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9529-9529
Author(s):  
B. Morris ◽  
R. Khan ◽  
D. Ledet ◽  
C. Howell ◽  
C. Pui ◽  
...  

9529 Background: The majority of children diagnosed with ALL over the past two decades have achieved long-term survival. This remarkable success is attributed in part to intensive central nervous system (CNS)-directed therapy that effectively prevents CNS relapse. Because treatment-related neurological morbidity is recognized but poorly characterized, the objective of this cross-sectional study was to estimate the prevalence of neurological symptoms and signs in long-term survivors of childhood ALL. Methods: After obtaining IRB approval, all long-term ALL survivors (≥ 5 years since diagnosis) aged 6–28 years who remained active patients at our institution were identified. All participants completed a questionnaire consisting of independent (and when possible validated) instruments designed to identify various neurological symptoms, as well as, a comprehensive and standardized neurologic examination by a board-certified neurologist. Results: Of the 433 potentially eligible subjects, 162 (37.4%) were enrolled. Participant demographic information and previous treatment exposure were similar to those not enrolled in the study. The rates of endorsed neurological symptoms were: neuropathy (40.1%), dizziness (33%), back pain (22.8%), fatigue (19.1%), falls (15.4%), headache (14.8%), seizures (10.5%), urinary incontinence (8.6%), and stroke (1.2%). Neurological examination confirmed an underlying sensory neuropathy in 44 patients (27.3%). Otherwise, signs of chronic cranial nerve dysfunction (1.9%) and motor weakness (5.6%) were rare. Conclusions: Symptoms and signs of a chronic sensory neuropathy, presumably from previous vincristine exposure, were evident in many patients. Complaints of fatigue, dizziness, and chronic back pain were also relatively common. The number of patients who routinely fall is of concern. Whether these falls are associated with symptoms/signs of neuropathy, weakness, and/or dizziness will require further analysis. Although headache was a common complaint, its prevalence may not differ significantly from a normal age-matched population. No significant financial relationships to disclose.


1985 ◽  
Vol 151 (6) ◽  
pp. 718-720 ◽  
Author(s):  
Mortimer G. Rosen ◽  
Sara Debanne ◽  
Karen Thompson ◽  
Robert M. Bilenker

Sign in / Sign up

Export Citation Format

Share Document